Coverage
-
May 22, 2012
A Delaware federal judge on Friday barred Mylan Pharmaceuticals Inc. from selling a generic version of Galderma Laboratories Inc.'s rosacea drug Oracea, even though the patent Mylan was found to have infringed was issued after its generic received government approval.
1 other articles on this case.
View all »